scholarly journals Yellow Fever Virus Vaccine Reduces T Cell Receptor Signaling and the Levels of Phosphatase PTPRE In Vivo

Proceedings ◽  
2020 ◽  
Vol 50 (1) ◽  
pp. 97
Author(s):  
Jinhua Xiang ◽  
James H. McLinden ◽  
Qing Chang ◽  
Thomas M Kaufman ◽  
Judy A. Streit ◽  
...  

Background: A Src kinase-activating phosphatase (PTPRE) is targeted by a genome-derived yellow fever virus (YFV) short noncoding RNA (vsRNA) in vitro. The vsRNA reduces PTPRE translation, which leads to reduced TCR signaling. vsRNA point mutations restore PTPRE expression and T cell function. We examined TCR signaling and PTPRE levels in individuals before and after YFV vaccination (YFVax). Methods: Fourteen individuals receiving YFVax (104.7–5.6) IM for travel prophylaxis provided written informed consent for these studies. Blood was obtained once before vaccination and four times after vaccination (days 3 to 28). Serum and PBMCs were purified and YFV was quantified by RNA and infectivity. PBMCs were assessed for activation following anti-CD3 stimulation by measuring phospho-tyrosine-394-Lck and IL-2 release. PBMC PTPRE levels were determined by immunoblot analyses (normalized to actin). A YFV-neutralizing antibody was determined by PRNT. Results: YFVax was administered alone (six out of 14 subjects) or in combination with other vaccines (eight out of 14). All subjects demonstrated reduced resting PBMC PTPRE levels and post-TCR stimulation had reduced IL-2 release between days 4 and 21 compared to pre- and day 28 samples. Phospho-Lck was reduced in all but two subjects on the same days, and both of these subjects also received an influenza vaccine. Low-level viremia was detected in 10/14 subjects, with infectious titers of 100/mL. Viremia was not detected in four out of 14 subjects. All recipients developed neutralizing antibodies by day 21. Conclusion: YFV vaccination regulates PBMC PTPRE levels 4–21 days after infection, despite the low to absent infectious YFV detected in serum, suggesting that enough YFV vsRNA is produced and released from cells to have a functional (and measurable) effect on T cell function. Studies are underway to determine if this is mediated by exosomes or defective particles containing the vsRNA that targets PTPRE. Furthermore, the association between PTPRE and TCR signaling confirms a role for PTPRE in TCR function.

2017 ◽  
Vol 216 (9) ◽  
pp. 1164-1175 ◽  
Author(s):  
James H McLinden ◽  
Nirjal Bhattarai ◽  
Jack T Stapleton ◽  
Qing Chang ◽  
Thomas M Kaufman ◽  
...  

Author(s):  
Karina Takesaki Miyaji ◽  
Vivian Iida Avelino-Silva ◽  
Marisol Simões ◽  
Marcos da Silva Freire ◽  
Carlos Roberto de Medeiros ◽  
...  

Immunology ◽  
2009 ◽  
Vol 128 (1pt2) ◽  
pp. e718-e727 ◽  
Author(s):  
Mary Dawn T. Co ◽  
Elizabeth D. Kilpatrick ◽  
Alan L. Rothman

2017 ◽  
Vol 48 (2) ◽  
pp. 258-272 ◽  
Author(s):  
Amandine Bovay ◽  
Vincent Zoete ◽  
Garry Dolton ◽  
Anna M. Bulek ◽  
David K. Cole ◽  
...  

Immunity ◽  
2020 ◽  
Vol 53 (1) ◽  
pp. 143-157.e8 ◽  
Author(s):  
Chin-San Loo ◽  
Jovylyn Gatchalian ◽  
Yuqiong Liang ◽  
Mathias Leblanc ◽  
Mingjun Xie ◽  
...  

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 368 ◽  
Author(s):  
Kexin Yan ◽  
Laura J. Vet ◽  
Bing Tang ◽  
Jody Hobson-Peters ◽  
Daniel J. Rawle ◽  
...  

Despite the availability of an effective, live attenuated yellow fever virus (YFV) vaccine (YFV 17D), this flavivirus still causes up to ≈60,000 deaths annually. A number of new approaches are seeking to address vaccine supply issues and improve safety for the immunocompromised vaccine recipients. Herein we describe an adult female IFNAR-/- mouse model of YFV 17D infection and disease that recapitulates many features of infection and disease in humans. We used this model to evaluate a new YFV vaccine that is based on a recently described chimeric Binjari virus (BinJV) vaccine technology. BinJV is an insect-specific flavivirus and the chimeric YFV vaccine (BinJ/YFV-prME) was generated by replacing the prME genes of BinJV with the prME genes of YFV 17D. Such BinJV chimeras retain their ability to replicate to high titers in C6/36 mosquito cells (allowing vaccine production), but are unable to replicate in vertebrate cells. Vaccination with adjuvanted BinJ/YFV-prME induced neutralizing antibodies and protected mice against infection, weight loss and liver pathology after YFV 17D challenge.


2010 ◽  
Vol 185 (4) ◽  
pp. 2295-2305 ◽  
Author(s):  
Satoshi Tanaka ◽  
Shinji Maeda ◽  
Motomu Hashimoto ◽  
Chihiro Fujimori ◽  
Yoshinaga Ito ◽  
...  

2009 ◽  
Vol 183 (12) ◽  
pp. 7919-7930 ◽  
Author(s):  
Rama S. Akondy ◽  
Nathan D. Monson ◽  
Joseph D. Miller ◽  
Srilatha Edupuganti ◽  
Dirk Teuwen ◽  
...  

AIDS ◽  
1998 ◽  
Vol 12 (13) ◽  
pp. 1591-1600 ◽  
Author(s):  
Patrizia Carotenuto ◽  
Dennis Looij ◽  
Lian Keldermans ◽  
Frank de Wolf ◽  
Jaap Goudsmit

Sign in / Sign up

Export Citation Format

Share Document